New Oral Anticoagulants in Venous Thromboembolism
dc.contributor.advisor | Boda, Zoltán | |
dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézet | hu_HU |
dc.contributor.author | Khamboo, Waseem | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Barta, Judit | |
dc.contributor.opponent | Rázsó, Katalin | |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Kardiológiai Intézet | hu_HU |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézet | hu_HU |
dc.date.accessioned | 2019-09-25T11:31:45Z | |
dc.date.available | 2019-09-25T11:31:45Z | |
dc.date.created | 2019-01-14 | |
dc.description.abstract | I have discussed the most important aspects of Vitamin K antagonist and NOAC’s. Having looked at their pharmacological profiles, indications and may other factors, it has allowed for a comparison of the 2 groups. The review of literature and clinical trials has provided further understanding and a strong comparison of their uses in different clinical scenarios. | hu_HU |
dc.description.corrector | LB | |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.coursespec | Orvosbiológia-farmakológia | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 34 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/273746 | |
dc.language.iso | en | hu_HU |
dc.subject | NOAC | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
dc.title | New Oral Anticoagulants in Venous Thromboembolism | hu_HU |